Drug Profile
Research programme: Crohn's disease therapeutics - Enterome/Janssen Biotech
Alternative Names: EB 110Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Enterome
- Class Anti-inflammatories; Bacterial proteins
- Mechanism of Action Gastrointestinal microbiome modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Crohn's disease
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Crohn's disease in USA (unspecified route) (Enterome pipeline, August 2023)
- 28 Aug 2019 No recent reports of development identified for preclinical development in Crohn's-disease in USA
- 07 Jan 2016 Enterome and Janssen Biotech enter into collaboration to develop Crohn's disease therapeutics for the treatment of Crohn's disease